{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:11:40Z","timestamp":1779923500346,"version":"3.53.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:00:00Z","timestamp":1457481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1053\/j.gastro.2016.02.078","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T20:33:18Z","timestamp":1457728398000},"page":"1590-1598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":236,"title":["Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease"],"prefix":"10.1053","volume":"150","author":[{"given":"Paul J.","family":"Pockros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvez S.","family":"Mantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0510-0417","authenticated-orcid":false,"given":"Eric","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy S.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Abunimeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Podsadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2016.02.078_bib1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.02.078_bib2","unstructured":"Hepatitis C information for health professionals. Centers for Disease Control and Prevention. Available at: http:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm. Accessed June 2,\u00a02014."},{"key":"10.1053\/j.gastro.2016.02.078_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.02.078_bib4","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1572-0241.2008.01981.x","article-title":"HCV in patients with end-stage renal disease","volume":"103","author":"Okoh","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.02.078_bib5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2004.12.014","article-title":"Hepatitis C infection is acquired pre-ESRD","volume":"45","author":"Bergman","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.gastro.2016.02.078_bib6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfh012","article-title":"The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study","volume":"19","author":"Jadoul","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.gastro.2016.02.078_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1086\/502058","article-title":"High prevalence of hepatitis C infection among patients receiving hemodialysis at an urban dialysis center","volume":"23","author":"Sivapalasingam","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1053\/j.gastro.2016.02.078_bib8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","article-title":"The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies","volume":"14","author":"Fabrizi","year":"2007","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2016.02.078_bib9","doi-asserted-by":"crossref","first-page":"e100790","DOI":"10.1371\/journal.pone.0100790","article-title":"Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2016.02.078_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12072-011-9284-9","article-title":"Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection","volume":"6","author":"Satapathy","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2016.02.078_bib11","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1097\/01.ASN.0000100127.54107.57","article-title":"Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"14","author":"Goodkin","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.gastro.2016.02.078_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000332385","article-title":"Kidney transplantation in the patient with hepatitis C virus infection","volume":"176","author":"Morales","year":"2012","journal-title":"Contrib Nephrol"},{"key":"10.1053\/j.gastro.2016.02.078_bib13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1365-2036.2003.01780.x","article-title":"Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients","volume":"18","author":"Fabrizi","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2016.02.078_bib14","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1572-0241.2003.07526.x","article-title":"Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety","volume":"98","author":"Russo","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.02.078_bib15","unstructured":"Rebetol (ribavirin USP) capsules, for oral use [package insert]. Whitehouse Station, NJ: Merck. Revised on May\u00a02015."},{"key":"10.1053\/j.gastro.2016.02.078_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4254\/wjh.v7.i2.213","article-title":"Management of patients with hepatitis C infection and renal disease","volume":"7","author":"Bunchorntavakul","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1053\/j.gastro.2016.02.078_bib17","unstructured":"Copegus (ribavirin) Tablets [package insert]. South San Francisco, CA: Genentech. Revised on August\u00a02011."},{"key":"10.1053\/j.gastro.2016.02.078_bib18","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.02.078_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrgastro.2015.53","article-title":"Treatment of hepatitis C in difficult-to-treat patients","volume":"12","author":"Ferenci","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2016.02.078_bib20","unstructured":"Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Available at: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm225333.pdf. Accessed September 1,\u00a02015."},{"key":"10.1053\/j.gastro.2016.02.078_bib21","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.02.078_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.02.078_bib23","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r\u2013ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.02.078_bib24","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.02.078_bib25","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2016.02.078_bib26","doi-asserted-by":"crossref","first-page":"S862","DOI":"10.14309\/00000434-201510001-02048","article-title":"Sustained virologic response rate of 96% in HCV genotype 1a-infected patients treated with ombitasvir\/paritaprevir\/r and dasabuvir with ribavirin","volume":"110","author":"Rustgi","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.02.078_bib27","doi-asserted-by":"crossref","first-page":"S850","DOI":"10.14309\/00000434-201510001-02016","article-title":"99.7% sustained virologic response rate in 369 HCV genotype 1b-infected patients treated with label-recommended regimen of ombitasvir\/paritaprevir\/r and dasabuvir with or without ribavirin","volume":"110","author":"Jacobson","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2016.02.078_bib28","first-page":"320A","article-title":"The pharmacokinetics and safety of the direct acting antiviral regimen of ABT-450\/r, ombitasvir with\/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function","volume":"60","author":"Khatri","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2016.02.078_bib29","unstructured":"Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [package insert]. North Chicago, IL: AbbVie, Inc. Revised on October\u00a02015."},{"key":"10.1053\/j.gastro.2016.02.078_bib30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","article-title":"Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?","volume":"19","author":"Fabrizi","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2016.02.078_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2016.02.078_bib32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2016.02.078_bib33","unstructured":"Sovaldi (sofosbuvir) tablets, for oral use [package insert]. Foster City, CA: Gilead Sciences. Revised on August\u00a02015."},{"key":"10.1053\/j.gastro.2016.02.078_bib34","unstructured":"Harvoni (ledipasvir and sofosbuvir) tablets [package insert]. Foster City, CA: Gilead Sciences. Revised on March\u00a02015."},{"key":"10.1053\/j.gastro.2016.02.078_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40268-015-0101-0","article-title":"Evaluation of the pharmacokinetics and renal excretion of simeprevir in subjects with renal impairment","volume":"15","author":"Ouwerkerk-Mahadevan","year":"2015","journal-title":"Drugs R D"},{"key":"10.1053\/j.gastro.2016.02.078_bib36","unstructured":"Daklinza (daclatasvir) tablets, for oral use [package insert]. Princeton, NJ: Bristol-Myers Squibb. Revised on July\u00a02015."}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516003267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508516003267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:12:04Z","timestamp":1758035524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508516003267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0016508516003267"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2016.02.078","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2016.02.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}